Endometrin

Endometrin is a brand name of progesterone, approved by the FDA in the following formulation(s):

ENDOMETRIN (progesterone - insert; vaginal)

• 
  Manufacturer: FERRING
  
  Approval date: June 21, 2007
  
  Strength(s): 100MG ^[RLD]

Has a generic version of Endometrin been approved?

No. There is currently no therapeutically equivalent version of Endometrin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Endometrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Vaginally administrable progesterone-containing tablets and method for preparing same
  Patent 7,300,664
  Issued: November 27, 2007
  Inventor(s): Jossifoff; Azariah
  Assignee(s): Ferring B.V.
  There is provided a method for preparing a tablet for the vaginal administration of progesterone for systemic use, comprising the steps of: slowly mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, whereby to obtain wetted micronized progesterone; drying said wetted, micronized progesterone to a humidity content of substantially 0%, whereby to form substantially dry micronized progesterone; mixing said substantially dry micronized progesterone with other pharmaceutically acceptable excipients or diluents therefor; and forming a tablet by direct compaction of said substantially dry micronized progesterone which has been mixed with said other pharmaceutically acceptable excipients or diluents therefor. Tablets so prepared, as well as a tablet comprising between about 6 to 20 wt. % progesterone and between about 5 to 12 wt. % effervescent, are also provided.
  
  Patent expiration dates:
  
  
  • November 17, 2019
    
    ✓ 
    Patent use: SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
  
  



• 
  Vaginally administrable progesterone-containing tablets and method for preparing same
  Patent 7,320,800
  Issued: January 22, 2008
  Inventor(s): Jossifoff; Azariah
  Assignee(s): Ferring B.V.
  The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.
  
  Patent expiration dates:
  
  
  • November 17, 2019
    
    ✓ 
    Patent use: SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPORDUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
  
  



• 
  Vaginally administratable progesterone-containing tablets and method for preparing same
  Patent 7,393,543
  Issued: July 1, 2008
  Inventor(s): Jossifoff; Azariah
  Assignee(s): Ferring B.V.
  The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.
  
  Patent expiration dates:
  
  
  • November 17, 2019
    
    ✓ 
    Patent use: ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
    ✓ 
    Drug product
  
  

See also...

• Endometrin Consumer Information (Drugs.com)
• Endometrin Insert Consumer Information (Wolters Kluwer)
• Endometrin Consumer Information (Cerner Multum)
• Progesterone Consumer Information (Drugs.com)
• Progesterone Consumer Information (Wolters Kluwer)
• Progesterone Gel Consumer Information (Wolters Kluwer)
• Progesterone Insert Consumer Information (Wolters Kluwer)
• Progesterone Oil Consumer Information (Wolters Kluwer)
• FIRST-Progesterone VGS 100 Consumer Information (Cerner Multum)
• FIRST-Progesterone VGS 200 Consumer Information (Cerner Multum)
• FIRST-Progesterone VGS 25 Consumer Information (Cerner Multum)
• FIRST-Progesterone VGS 400 Consumer Information (Cerner Multum)
• FIRST-Progesterone VGS 50 Consumer Information (Cerner Multum)
• Progesterone Consumer Information (Cerner Multum)
• Progesterone vaginal Consumer Information (Cerner Multum)
• Progesterone AHFS DI Monographs (ASHP)